Cargando…

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer

BACKGROUND: STX2484 is a novel non-steroidal compound with potent anti-proliferative activity. These studies aimed to identify STX2484's mechanism of action, in vivo efficacy and activity in taxane-resistant breast cancer models. METHODS: Effects of STX2484 and paclitaxel on proliferation, cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stengel, C, Newman, S P, Day, J M, Chander, S K, Jourdan, F L, Leese, M P, Ferrandis, E, Regis-Lydi, S, Potter, B V L, Reed, M J, Purohit, A, Foster, P A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102933/ https://www.ncbi.nlm.nih.gov/pubmed/24960406 http://dx.doi.org/10.1038/bjc.2014.188

Ejemplares similares

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
por: Day, J M, et al.
Publicado: (2009)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
por: Chander, S K, et al.
Publicado: (2007)

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
por: Newman, S P, et al.
Publicado: (2007)

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
por: Tagg, S L C, et al.
Publicado: (2008)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis
por: Follet, J, et al.
Publicado: (2012)

βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer
por: Christoph, D C, et al.
Publicado: (2012)

The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer
por: Parsons, M F C, et al.
Publicado: (2008)

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
por: Bartlett, J M S, et al.
Publicado: (2015)

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition
por: Duran, George E, et al.
Publicado: (2017)

Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol
por: Shen, Yu-chi, et al.
Publicado: (2015)

Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents
por: Ireson, C R, et al.
Publicado: (2004)

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
por: Reed, M D, et al.
Publicado: (2013)

Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats
por: Ireson, C R, et al.
Publicado: (2004)

Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin
por: Korbelik, M, et al.
Publicado: (2007)

The pro-apoptotic role of autophagy in breast cancer
por: Suman, S, et al.
Publicado: (2014)

Identification of novel vascular targets in lung cancer
por: Zhuang, X, et al.
Publicado: (2015)

Effects of adiponectin on breast cancer cell growth and signaling
por: Grossmann, M E, et al.
Publicado: (2008)

Pharmacological targeting of NF-κB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells
por: Lagadec, P, et al.
Publicado: (2008)

Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells
por: van Bree, C, et al.
Publicado: (2008)

Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells
por: Vaz, A P, et al.
Publicado: (2014)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

Phenformin as prophylaxis and therapy in breast cancer xenografts
por: Appleyard, M V C L, et al.
Publicado: (2012)

Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation
por: Lopergolo, A, et al.
Publicado: (2009)

The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer
por: Someya, M, et al.
Publicado: (2011)

Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005)

Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy
por: Koukourakis, M I, et al.
Publicado: (2014)

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005)

Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia
por: Sanders, P M, et al.
Publicado: (2005)

Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis
por: Schulz, P, et al.
Publicado: (2008)

Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice
por: Dahm, F, et al.
Publicado: (2008)

Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells
por: Suman, S, et al.
Publicado: (2013)

The neuro-steroid, 3β androstene 17α diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathways
por: Graf, M R, et al.
Publicado: (2007)

Treatment decisions and survival for people with small-cell lung cancer
por: Powell, H A, et al.
Publicado: (2014)

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
por: Wattenberg, M M, et al.
Publicado: (2014)

High-energy particle beam and gamma radiation exposure, familial relatedness and cancer in mice
por: Chernyavskiy, Pavel, et al.
Publicado: (2017)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice
por: Bing, C, et al.
Publicado: (2006)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6tbfqeigibvgmfpdjjko48niou